Relistor Expansion Plans In Question Following “Complete Response” Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA requested more clinical data on Salix/Progenics’ sNDA for approval of the subcutaneous formulation of methylnaltrexone in chronic, non-cancer pain patients with opioid-induced constipation. The regulatory setback could have implications for the companies’ planned September filing of an oral formulation in the same patient population.
You may also be interested in...
Progenics Finds New Partner For Relistor In Salix
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.
Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too
Compound helps bowel function in dying patients on opioids.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.